T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines

AIDS Research and Human Retroviruses

Volumn 26, Issue 1, 2010, Pages 51-59

  Weinberg, Adriana ^a   Song, Lin Ye ^b   Fenton, Terence ^b   Nachman, Sharon A ^c   Read, Jennifer S ^d   Patterson Bartlett, Julie ^a   Levin, Myron J ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Biostatistics in AIDS Research   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INFLUENZA VACCINE; PHYTOHEMAGGLUTININ;

ADOLESCENT; ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; VIRUS STRAIN;

ADOLESCENT; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOASSAY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INTERFERON-GAMMA; MALE; TIME FACTORS; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 76449086947     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0163     Document Type: Article

References (49)

1. Malaspina A, Moir S, Orsega SM, et al.: Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005;191:1442-1450.
2. Tasker SA, O'Brien WA, Treanor JJ, et al.: Effects of influenza vaccination in HIV-infected adults: A double-blind, placebocontrolled trial. Vaccine 1998;16:1039-1042.
3. King JC, Jr, Fast PE, Zangwill KM, et al.: Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001;20:1124-1131.
4. King JC, Jr, Treanor J, Fast PE, et al.: Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live coldadapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000;181:725-728.
5. Levin MJ, Song LY, Fenton T, et al.: Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008;26:4210-4217.
6. Rhorer J, Ambrose CS, Dickinson S, et al.: Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine 2009;27:1101-1110.
7. Belshe RB, Edwards KM, Vesikari T, et al.: Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685-696.
8. Belshe RB, Gruber WC, Mendelman PM, et al.: Correlates of immune protection induced by live, attenuated, coldadapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000;181:1133-1137.
9. Belshe RB, Mendelman PM, Treanor J, et al.: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998;338:1405-1412.
10. Brown DM, Dilzer AM, Meents DL, and Swain SL: CD4 T cell-mediated protection from lethal influenza: Perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 2006;177:2888-2898.
11. Cerwenka A, Morgan TM, and Dutton RW: Naive, effector, and memory CD8 T cells in protection against pulmonary nfluenza virus infection: Homing properties rather than initial frequencies are crucial. J Immunol 1999;163:5535-5543.
12. Mbawuike IN, Piedra PA, Cate TR, and Couch RB: Cytotoxic T lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine. J Med Virol 1996;50:105-111.
13. Mbawuike IN, Zhang Y, and Couch RB: Control of mucosal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes. Respir Res 2007;8:44.
14. McElhaney JE, Xie D, Hager WD, et al.: T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006;176:6333-6339.
15. He XS, Holmes TH, Mahmood K, et al.: Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J Infect Dis 2008; 197:803-811.
16. He XS, Holmes TH, Zhang C, et al.: Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006;80:11756-11766.
17. He XS, Mahmood K, Maecker HT, et al.: Analysis of the frequencies and of the memory T cell phenotypes of human CD8+ T cells specific for influenza A viruses. J Infect Dis 2003;187:1075-1084.
18. Forrest BD, Pride MW, Dunning AJ, et al.: Correlation of cellular immune responses with protection against cultureconfirmed influenza virus in young children. Clin Vaccine Immunol 2008;15:1042-1053.
19. D'Orsogna LJ, Krueger RG, McKinnon EJ, and French MA: Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS 2007;21:1747-1752.
20. Moir S, Ho J, Malaspina A, et al.: Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008; 205:1797-1805.
21. Viau M, Veas F, and Zouali M: Direct impact of inactivated HIV-1 virions on B lymphocyte subsets. Mol Immunol 2007;44:2124-2134.
22. Miiro G, Kayhty H, Watera C, et al.: Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005;192:1801-1805.
23. Weinberg A, Huang S, Fenton T, et al.: Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on HAART. J Acquir Immune Defic Syndr 2009;52:17-24.
24. Weinberg A, Dickover R, Britto P, et al.: Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS 2008;22:2267-2277.
25. Hahn G and Meeker WQ: Statistical Intervals: A Guide for Practitioners. John Wiley & Sons, New York, 1991.
26. Avetisyan G, Ragnavolgyi E, Toth GT, Hassan M, and Ljungman P: Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stemcell transplant recipients. Bone Marrow Transplant 2005;36:411-415.
27. Zeman AM, Holmes TH, Stamatis S, et al.: Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 2007;26:107-115.
28. Tanzi E, Esposito S, Bojanin J, et al.: Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006;78: 440-445.
29. Vigano A, Zuccotti GV, Pacei M, et al.: Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008;48:289-296.
30. Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, and D'Souza M P: Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 2005;21:68-81.
31. Janetzki S, Panageas KS, Ben-Porat L, et al.: Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2008; 57:303-315.
32. Hammitt LL, Li S, Patterson-Bartlett J, et al.: Kinetics of viral shedding and immune responses to cold-adapted influenza vaccine. In: X International Symposium on Respiratory Viral Infections, Singapore, Thailand, Feb 28-Mar 2, 2008.
33. Hyjek E, Lischner HW, Hyslop T, et al.: Cytokine patterns during progression to AIDS in children with perinatal HIV infection. J Immunol 1995;155:4060-4071.
34. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, and Nixon DF: Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004;78:2454-2459.
35. Andersson J, Boasso A, Nilsson J, et al.: The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol 2005;174:3143-3147.
36. Eggena MP, Barugahare B, Jones N, et al.: Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol 2005;174:4407-4414.
37. Tsunemi S, Iwasaki T, Imado T, et al.: Relationship of CD4+ CD25+ regulatory T cells to immune status in HIV-infected patients. AIDS 2005;19:879-886.
38. Dhodapkar MV and Steinman RM: Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 2002;100:174-177.
39. Krathwohl MD, Schacker TW, and Anderson JL: Abnormal presence of semimature dendritic cells that induce regulatory T cells in HIV-infected subjects. J Infect Dis 2006;193: 494-504.
40. Mavilio D, Lombardo G, Kinter A, et al.: Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med 2006; 203:2339-2350.
41. Tretter T, Venigalla RK, Eckstein V, et al.: Induction of CD4+ T-cell anergy and apoptosis by activated human B cells. Blood 2008;112:4555-4564.
42. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, and Chernoff D: Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: Impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999;28:541-547.
43. Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, and Saah AJ: The effect of influenza vaccination on human immunodeficiency virus type 1 load: A randomized, double-blind, placebo-controlled study. J Infect Dis 1996;174:1332-1336.
44. Keller M, Deveikis A, Cutillar-Garcia M, et al.: Pneumococcal and influenza immunization and human immunodeficiency virus load in children. Pediatr Infect Dis J 2000;19:613-618.
45. O'Brien WA, Grovit-Ferbas K, Namazi A, et al.: Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-1089.
46. Stanley SK, Ostrowski MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-1230.
47. Staprans SI, Hamilton BL, Follansbee SE, et al.: Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727-1737.
48. Loffredo JT, Burwitz BJ, Rakasz EG, et al.: The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape. J Virol 2007;81:2624-2634.
49. Schmitz JE, Kuroda MJ, Santra S, et al.: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-860.